Indeed, we demonstrated that inhibition of PBK reduced myeloma cell growth and enhanced lenalidomide and bortezomib activity in the IMiD‐resistant cell lines JJN3 and XG1LenRes (Figure S6). The gene discussed is PBK; the disease is plasma cell myeloma.